Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;28(2):660-669.
doi: 10.1111/ene.14592. Epub 2020 Nov 21.

Clinical correlations and long-term follow-up in 100 patients with sarcoglycanopathies

R Guimarães-Costa  1 , G Fernández-Eulate  1 , K Wahbi  1 , F Leturcq  2 , E Malfatti  3 , A Behin  1 , S Leonard-Louis  1 , I Desguerre  4 , C Barnerias  4 , M C Nougues  5 , A Isapof  5 , B Estournet-Mathiaud  6 , S Quijano-Roy  6 , A Fayssoil  7 , D Orlikowski  8 , B Fauroux  9 , I Richard  10 , C Semplicini  11 , N B Romero  12 , G Querin  1 , B Eymard  1 , P Laforêt  13 , T Stojkovic  1
Affiliations
Free article

Clinical correlations and long-term follow-up in 100 patients with sarcoglycanopathies

R Guimarães-Costa et al. Eur J Neurol. 2021 Feb.
Free article

Abstract

Background and purpose: To describe a large series of patients with α, β, and γ sarcoglycanopathies (LGMD-R3, R4, and R5) and study phenotypic correlations and disease progression.

Methods: A multicentric retrospective study in four centers in the Paris area collecting neuromuscular, respiratory, cardiac, histologic, and genetic data. The primary outcome of progression was age of loss of ambulation (LoA); disease severity was established according to LoA before or after 18 years of age. Time-to-event analysis was performed.

Results: One hundred patients (54 γ-SG; 41 α-SG; 5 β-SG) from 80 families were included. The γ-SG patients had earlier disease onset than α-SG patients (5.5 vs. 8 years; p = 0.022) and β-SG patients (24.4 years). Axial muscle weakness and joint contractures were frequent and exercise intolerance was observed. At mean follow-up of 22.9 years, 65.3% of patients were wheelchair-bound (66.7% α-SG, 67.3% γ-SG, 40% β-SG). Dilated cardiomyopathy occurred in all sarcoglycanopathy subtypes, especially in γ-SG patients (p = 0.01). Thirty patients were ventilated and six died. Absent sarcoglycan protein expression on muscle biopsy and younger age at onset were associated with earlier time to LoA (p = 0.021 and p = 0.002). Age at onset was an independent predictor of both severity and time to LoA (p = 0.0004 and p = 0.009). The α-SG patients showed genetic heterogeneity, whereas >90% of γ-SG patients carried the homozygous c.525delT frameshift variant. Five new mutations were identified.

Conclusions: This large multicentric series delineates the clinical spectrum of patients with sarcoglycanopathies. Age at disease onset is an independent predictor of severity of disease and LoA, and should be taken into account in future clinical trials.

Keywords: genetic; limb-girdle muscular dystrophies; neuromuscular diseases; outcome measures; sarcoglycan.

PubMed Disclaimer

References

    1. Duggan DJ, Gorospe JR, Fanin M, et al. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 1997; 336: 618-624.
    1. Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol 2015; 5: 1223-1239.
    1. Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol. 2014; 33: 1-12.
    1. Trabelsi M, Kavian N, Daoud F, et al. Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet. 2008; 16: 793-803.
    1. Dalichaouche I, Sifi Y, Roudaut C, et al. γ-sarcoglycan and dystrophin mutation spectrum in an Algerian cohort. Muscle Nerve 2017; 56: 129-135.